- Home
- RSSS vs STRO Comparison
RSSS vs STRO Comparison
Compare RSSS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSSS | STRO |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.7M | 85.0M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | RSSS | STRO |
|---|---|---|
| Price | $2.27 | $21.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $18.50 |
| AVG Volume (30 Days) | 84.6K | ★ 126.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.77 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $28,793,922.00 | N/A |
| Revenue This Year | $1.81 | $63.08 |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $57.50 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $2.15 | $0.52 |
| 52 Week High | $4.12 | $27.96 |
Technical Indicators
Market Signals| Indicator | RSSS | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 51.19 |
| Support Level | $2.15 | $0.76 |
| Resistance Level | $2.95 | $27.96 |
| Average True Range (ATR) | 0.09 | 2.22 |
| MACD | 0.01 | -0.47 |
| Stochastic Oscillator | 33.91 | 25.34 |
Price Performance
Historical ComparisonAbout RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.